JP2024515885A - パーキンソン病を処置及びモニタリングするための方法 - Google Patents

パーキンソン病を処置及びモニタリングするための方法 Download PDF

Info

Publication number
JP2024515885A
JP2024515885A JP2023566921A JP2023566921A JP2024515885A JP 2024515885 A JP2024515885 A JP 2024515885A JP 2023566921 A JP2023566921 A JP 2023566921A JP 2023566921 A JP2023566921 A JP 2023566921A JP 2024515885 A JP2024515885 A JP 2024515885A
Authority
JP
Japan
Prior art keywords
compound
subject
lrrk2
disease
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566921A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515885A5 (cg-RX-API-DMAC10.html
Inventor
ジェニングス,ダナ・エル
ダーヤニ,ヴィナイ・エム
ハントワーク-ロドリゲス,サラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of JP2024515885A publication Critical patent/JP2024515885A/ja
Publication of JP2024515885A5 publication Critical patent/JP2024515885A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2023566921A 2021-04-30 2022-04-29 パーキンソン病を処置及びモニタリングするための方法 Pending JP2024515885A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163182207P 2021-04-30 2021-04-30
US63/182,207 2021-04-30
PCT/US2022/026898 WO2022232487A1 (en) 2021-04-30 2022-04-29 Methods for treating and monitoring parkinson's disease

Publications (2)

Publication Number Publication Date
JP2024515885A true JP2024515885A (ja) 2024-04-10
JP2024515885A5 JP2024515885A5 (cg-RX-API-DMAC10.html) 2025-05-09

Family

ID=83847331

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566921A Pending JP2024515885A (ja) 2021-04-30 2022-04-29 パーキンソン病を処置及びモニタリングするための方法

Country Status (9)

Country Link
US (1) US20240207266A1 (cg-RX-API-DMAC10.html)
EP (1) EP4329763A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024515885A (cg-RX-API-DMAC10.html)
CN (1) CN117769422A (cg-RX-API-DMAC10.html)
AU (1) AU2022267325A1 (cg-RX-API-DMAC10.html)
CA (1) CA3217230A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023012851A (cg-RX-API-DMAC10.html)
TW (1) TW202308635A (cg-RX-API-DMAC10.html)
WO (1) WO2022232487A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025051214A1 (zh) * 2023-09-07 2025-03-13 上海翊石医药科技有限公司 一种芳杂环类化合物及其制备方法
CN121226329A (zh) * 2024-06-28 2025-12-30 成都康弘药业集团股份有限公司 一种治疗或预防lrrk2介导的疾病的化合物
CN119119035B (zh) * 2024-08-30 2025-11-04 中山大学 一种ripk1激酶靶点抑制剂及其制备方法与应用
CN118878521B (zh) * 2024-09-26 2025-02-14 苏州美诺医药科技有限公司 一种lrrk2抑制剂的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019521984A (ja) * 2016-06-16 2019-08-08 デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. 神経変性疾患の治療に用いるlrrk2阻害剤としてのピリミジン−2−イルアミノ−1h−ピラゾール

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013164323A1 (en) * 2012-05-03 2013-11-07 F. Hoffmann-La Roche Ag Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease
WO2014059052A1 (en) * 2012-10-09 2014-04-17 Uab Research Foundation Methods and compositions for diagnosis and treatment of parkinson's disease and parkinsonism

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019521984A (ja) * 2016-06-16 2019-08-08 デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. 神経変性疾患の治療に用いるlrrk2阻害剤としてのピリミジン−2−イルアミノ−1h−ピラゾール

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FRONTIERS IN NEUROSCIENCE, vol. Volume 14, Article 498, JPN6026022526, 2020, ISSN: 0005875038 *
MOVEMENT DISORDERS, vol. 34, no. 3, JPN6026022527, 2019, pages 406 - 415, ISSN: 0005875039 *
MOVEMENT DISORDERS, vol. 35, no. 1, JPN6026022528, 2020, pages 134 - 141, ISSN: 0005875040 *

Also Published As

Publication number Publication date
US20240207266A1 (en) 2024-06-27
AU2022267325A1 (en) 2023-11-16
EP4329763A4 (en) 2025-03-05
MX2023012851A (es) 2024-03-19
EP4329763A1 (en) 2024-03-06
TW202308635A (zh) 2023-03-01
CN117769422A (zh) 2024-03-26
CA3217230A1 (en) 2022-11-03
WO2022232487A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
US20240207266A1 (en) Methods for treating and monitoring parkinson's disease
RU2759856C1 (ru) Новое соединение для прямого ингибирования активности asm, представляющее собой производное 2-амино-2-(1,2,3-триазол-4-ил)пропан-1,3-диола, и его применение
Elkalioubie et al. Near-fatal tramadol cardiotoxicity in a CYP2D6 ultrarapid metabolizer
Rafehi et al. Highly variable pharmacokinetics of tyramine in humans and polymorphisms in OCT1, CYP2D6, and MAO-A
JP2012508737A5 (cg-RX-API-DMAC10.html)
Mahoney-Crane et al. Neuronopathic GBA1L444P mutation accelerates glucosylsphingosine levels and formation of hippocampal alpha-synuclein inclusions
TW201142297A (en) Urinary triaosylceramide (Gb3) as a marker of cardiac disease
WO2023083288A1 (en) TREATMENT OF LIVER DISORDERS WITH A THR-β AGONIST
CN119013027A (zh) 用于治疗肝脏病症的SSAO抑制剂和THR-β激动剂的组合
EP3704092A1 (en) Isoindoline compositions and methods for treating neurodegenerative disease
JP5713887B2 (ja) 筋変性疾患の検出方法、及び治療効果判定方法
US20250177351A1 (en) Isoindoline compositions and methods for treating neurodegenerative disease
Tan et al. Rat hair metabolomics analysis reveals perturbations of unsaturated fatty acid biosynthesis, phenylalanine, and arachidonic acid metabolism pathways are associated with amyloid-β-induced cognitive deficits
Maloney et al. LRRK2 kinase activity regulates Parkinson’s disease-relevant lipids at the lysosome
Patterson et al. Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein
Zhang et al. Mechanisms of the active components from Korean pine nut preventing and treating d-galactose-induced aging rats
Sadybekov et al. Development of potent, selective cPLA2 inhibitors for targeting neuroinflammation in Alzheimer’s disease and other neurodegenerative disorders
US12576055B2 (en) Disease detection and treatment based on trimethyl-lysine levels
Suhre et al. Identification of a potential biomarker for FABP4 inhibition: the power of lipidomics in preclinical drug testing
Liu et al. Absorption, tissue disposition, and excretion of fasudil hydrochloride, a RHO kinase inhibitor, in rats and dogs
Ikuno et al. Mitochondrial dysfunction in a mouse model of prodromal Parkinson’s disease: A metabolomic analysis
TW201805004A (zh) 用於預防具風險病患之阿茲海默症之㗁衍生物
JP2026507930A (ja) グルコセレブロシダーゼアクチベータを使用した患者におけるパーキンソン病の処置
US20240295566A1 (en) Method for diagnosing and treating metabolic disorders
US20250302775A1 (en) Methods for the treatment of depression

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260602